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Using CPAP in COVID-19 patients outside
of the intensive care setting: a comparison
of survival and outcomes between dialysis
and non-dialysis dependent patients
Lauren Floyd1* , Madelena Stauss1, Joshua Storrar1, Parthvi Vanalia1, Anna France2 and Ajay Dhaygude1
Abstract
Background: SARS-CoV-2 (COVID-19) is a novel coronavirus associated with high mortality rates. The use of
Continuous Positive Airway Pressure (CPAP) has been recognised as a management option for severe COVID-19
(NHS, Specialty guides for patient management during the coronavirus pandemic Guidance for the role and use of
non-invasive respiratory support in adult patients with coronavirus (confirmed or suspected), https://www.nice.org.
uk/guidance/ng159). We offered ward-based CPAP to COVID-19, dialysis patients not suitable for escalation to ICU.
The aim of the study was to evaluate the use of CPAP for COVID-19 dialysis patients compared to non-dialysis
COVID-19 patients outside of the intensive care setting. We further aimed to investigate factors associated with
improved outcomes.
Methods: Data was collected from a single centre (Royal Preston Hospital, UK), from March to June 2020.
Treatment outcomes were compared for dialysis and non-dialysis dependent patients who received CPAP with
limitations on their escalation and resuscitation status. Kaplan-Meier survival curves and Cox regression models were
used to compare outcomes. The primary study outcome was 30 day mortality. Confounders including length of
admission, systemic anticoagulation and ultrafiltration volumes on dialysis were also analysed.
Results: Over the study period, 40 dialysis patients tested positive for COVID-19, with 30 requiring hospital
admission. 93% (n = 28) required supplementary oxygen and 12% (n = 9) required CPAP on the ward. These patients
were compared to a serial selection of 14 non-dialysis patients treated with CPAP during the same period. Results
showed a significant difference in 30 day survival rates between the two groups: 88.9% in the dialysis group vs.
21.4% in the non-dialysis group. Statistical modelling showed that anticoagulation was also an important factor and
correlated with better outcomes.
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Conclusion: This is to the best of our knowledge, the largest series of COVID-19 dialysis patients treated with CPAP
in a ward-based setting. In general, dialysis dependent patients have multiple co-morbidities including
cardiovascular disease and diabetes mellitus making them vulnerable to COVID-19 and not always suitable for
treatment in ICU. We showed a significantly lower 30 day mortality rate with the use of CPAP in the dialysis group
(11.1%) compared to the non-dialysis group (78.6%). Despite a small sample size, we believe this study provides
impetus for further work clarifying the role of CPAP in treating COVID-19 dialysis dependent patients.
Keywords: CPAP, COVID-19, Dialysis, Anticoagulation
Background
SARS-CoV-2 (COVID-19) is a novel coronavirus which
has become a global pandemic in the space of a few
months. The presentation, course and definitive treat-
ment of the virus remains unclear with continually
emerging evidence. Royal Preston Hospital is in the
North West of England and serves a population of
1.5million, with a total of 610 dialysis patients; home
haemodialysis (HHD), in-centre haemodialysis (ICHD)
and peritoneal dialysis (PD). Following the trajectory of
London’s dialysis population experience, which was
roughly 3–4 weeks ahead of the North West, we antici-
pated a worst case scenario of 20–22% of our dialysis pa-
tients testing positive for COVID-19 [1]. Based on this
assumption, the number of patients (~ 120) in our re-
gion potentially requiring hospital admission and further
treatment such as Continuous Positive Airway Pressure
(CPAP) would have exceeded the capacity of our centre’s
intensive care unit (ICU) by two-fold. With this projec-
tion and compounded by the frailty and multimorbid na-
ture of our dialysis patients, we looked at delivering
CPAP as a ward-based treatment. Medical and nursing
teams, including dialysis staff received education from
the respiratory department in how to effectively set up,
commence and manage CPAP.
The role of CPAP was recognised early on as a man-
agement option in severe COVID-19 but its efficacy re-
mains unknown. CPAP is a form of respiratory support
that can be used to help patients with respiratory dis-
tress, type 1 respiratory failure and increasing oxygen re-
quirements. It has been recognised as important in the
management of COVID-19 patients and was advised by
NHS England early in the pandemic [2]. The role of
CPAP in the COVID-19 pandemic is 2 fold; one as a
treatment option for those not suitable for intubation
and ventilation, and the second as a method of relieving
unprecedented pressure on ICU’s [3]. The use of CPAP
in the intensive care setting has been used for many de-
cades as a management option for pulmonary oedema
and acute respiratory distress. However, its use as a
ward-based treatment in those with limitations of care is
less common and often limited to high dependency and
respiratory high care settings.
Our study looked at the use of CPAP as a ceiling of
care treatment in COVID-19 dialysis dependent patients
who were not suitable for escalation to level 2 or 3 care,
defined as patients requiring greater levels of observation
and intervention or those needing advanced respiratory
support together with the support of at least two organ
systems [4]. Offering CPAP for dialysis patients in a
renal ward was a novel service development we imple-
mented due to limited access to ICU beds. We were able
to successfully deliver this new service with rapid train-
ing of all ward-based staff in a very short period of time.
The objectives of the study were to describe the out-
comes for COVID-19 dialysis patients compared to non-
dialysis COVID-19 patients treated with CPAP outside
the intensive care setting and to further investigate fac-
tors associated with improved outcomes.
Methods
The patients included in this study were dialysis
dependent (HD, ICHD, PD) with COVID-19 who re-
quired respiratory support in the form of CPAP. All pa-
tients included received CPAP, two of whom were
already on nocturnal CPAP for obstructive sleep apnoea
at home but required escalation to 24 h respiratory
support. CPAP was delivered on the renal ward with
educational and clinical support from the respiratory
department. Dialysis was offered simultaneously with
CPAP and patients were nursed in cohorted bays with
full Personal Protective Equipment (PPE).
Single centre, real time data collection occurred from
24th March until 1st June 2020 (the peak incidence in
our region). The following data was collected: patient
demographics, clinical frailty scores (CFS), escalation
status, length of stay, indications for CPAP as well as fre-
quency of dialysis and ultrafiltration volumes. Primary
outcome measures were overall patient survival and 30
day mortality. Investigations were reviewed including
laboratory parameters, imaging and the use of procalci-
tonin as a marker of bacterial infection. We also mea-
sured outcomes looking at tolerance and duration of
CPAP as well as length of hospital admission.
Fourteen non dialysis patients were included in this
study. The patients included were consecutive patients
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admitted to the respiratory medical ward during the
peak study period who required CPAP, but who were
not felt to be suitable for escalation to level 3 care. This
was based on clinical assessments made by the medical
team on admission that took into account the degree of
co-morbidities and clinical frailty score, which included
assessment of patient’s functional baseline.
Univariate summaries were used to explore the data.
With regards to demographics and comorbidities, cross
tabulations of each variable against dialysis group were
used to examine the differences between the dialysis and
non-dialysis groups. Kaplan-Meier survival curves were
used to explore factors related to 30 day mortality and
Cox proportional hazards modelling was used to assess
the significance of these factors for survival. All statis-
tical analyses were conducted in R version 3.6.1. Ethics
approval and consent to participate were not applicable
to this study.
Results
Over the study period, 40 dialysis patients tested positive
for COVID-19, with 30 requiring admission to hospital
for COVID-19 related illness. Of these 30 patients, 93%
(n = 28) required supplementary oxygen therapy and
12% (n = 9) deteriorated requiring treatment with CPAP
on the ward. Of those that received CPAP the average
CFS was 5, which was defined as people who have evi-
dence of slowing, needing help with activities of daily liv-
ing (ADL’s) and are unable to walk outside alone [5].
The dialysis cohort were compared with 14 general med-
ical patients who were not dialysis dependent but were
co-morbid (Table 1) and not felt to be suitable for escal-
ation to level 3 care.
Dialysis patients had a higher proportion of males
compared to the non-dialysis group (77.8% vs 57.1% re-
spectively). Clinical frailty scores (5 vs 4) were similar
between the dialysis and non-dialysis groups respectively
(Table 1). Considering age, while the median ages dif-
fered by only 1.5 years, the interquartile range (IQR)
showed a generally older age distribution in those not
receiving dialysis (Table 1). The incidence of chronic
lung disease and ischemic heart disease was similarly
proportioned between the dialysis and non-dialysis
groups. The non-dialysis patients had a median eGFR of
64 ml/min with five patients having an eGFR of > 90ml/
min on admission, meaning this cohort was predomin-
antly free from CKD. CKD is considered as a risk factor
for poor outcomes in COVID-19 [6].
Exploratory analysis using univariate Cox regression,
modelling each variable separately for survival, did not
detect a significant difference in gender or history of
chronic lung disease and ischemic heart disease on 30
day survival for the sample as a whole. Furthermore,
whilst not statistically significant, univariate Cox regres-
sion demonstrated a poorer prognosis in older patients
over 80 years, whilst those under 60 years had an in-
creased chance of survival. We noted that, all patients
aged over 80 were in the non-dialysis group and all
those under 60 were in the dialysis group within this
sample. Although not validated in large populations, a
‘COVID age’ can be calculated based on patients risk
factors including age, gender, ethnicity and co-
morbidities [7]. Evidence suggests a significantly higher
‘COVID age’ is associated with end stage renal disease
and increased mortality. For example a calculated
‘COVID age’ of a 60 year old, Caucasian dialysis patient
would be 83 years [7, 8]. When calculating the ‘COVID
Table 1 Comparisons in demographics, co-morbidities and primary outcomes across the study and between the non dialysis and
dialysis groups
Total (n = 23) Dialysis Dependent (n = 9) Non-Dialysis (n = 14)
Demographics
Age (years),Median (IQR) 70 (66–78) 70 (53–71) 71.5 (66–80)
Sex
Male, n (%) 15 (65.3) 7 (77.8) 8 (57.1)
Female, n (%) 8 (34.7) 2 (22.2) 6 (42.9)
Clinical Frailty Score, Median 4.7 5.4 4.3
Disease Burden
eGFR (ml/min), Median 64
Procalcitonin (ng/ml),Median 1.58 3.89 0.43
Hx chronic lung disease, n (%) 6 (26.1) 2 (22.2) 4 (28.6)
Hx ischemic heart disease, n (%) 18 (78.2) 7 (77.8) 11 (78.6)
Primary outcomes
30 day mortality, n (%) 12 (56.5) 1 (11.1) 11 (78.6)
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age’ of our cohorts, the dialysis patients had a markedly
higher average ‘COVID age’ of 110.7 years compared to
the non-dialysis group (86 years).
All patients had a positive viral PCR nasopharyngeal
swab for SARS-CoV-2 and received CPAP in a ward-
based setting. Two (22.2%) patients were discussed with
critical care regarding suitability for escalation and only
one patient was admitted for CPAP in the ICU setting,
where they were initiated on CPAP and later stepped
down for ongoing CPAP on the ward. No patients were
considered for intubation and ventilation or cardiopul-
monary resuscitation across both groups. All patients
had a documented ceiling of care decision made, with
89% having this decision made prior to commencing
CPAP. Seventy seven percent had evidence of COVID-
19 related chest x-ray changes at the time of starting
CPAP. Two patients in the renal dialysis group and three
in the non-dialysis group started CPAP but failed to tol-
erate the therapy and withdrew from CPAP within 48 h.
Patients initiated on CPAP met the criteria based on
tachypnoea with a respiratory rate of over 25 breaths per
minute along with oxygen requirements of over 40% in-
spired oxygen (FiO2 0.4). Across the dialysis and non-
dialysis groups, the median time spent on CPAP was 6
days and 5.5 days respectively, with one dialysis
dependent patient requiring 15 days of respiratory sup-
port. CPAP settings were similar across both cohorts,
most patients required a maximum FiO2 of 0.6 (60% in-
spired oxygen) and the average Positive End Expiratory
Pressure (PEEP) achieved was 12 cmH2O, with one pa-
tient requiring a PEEP of 16 cmH2O.
Analysis of the effect of dialysis on the primary out-
come using Cox regression detected a statistically signifi-
cant difference in 30 day survival rate (p = 0.012). Thirty
day survival was 88.9% in the dialysis group and 21.4%
in the non-dialysis group, and the univariate Cox regres-
sion model (Table 2) suggested being on dialysis was as-
sociated with a 93% decrease in hazard of 30 day
mortality compared to not being on dialysis (Fig. 1). The
average length of stay in the dialysis group was much
higher at 26.5 days compared to the non-dialysis group
which was 12.2 days. This is likely to be explained by the
difference in mortality data and reflects that many of the
non-dialysis patients had died by day 10 of admission
(Fig. 1).
In the dialysis dependent cohort patients received
standard treatment with intermittent hemodiafiltration
(HDF) and high flux dialyzers. The majority of patients
(78%) received daily or alternate day dialysis for a
duration of 2–4 h each session. There was an average
ultrafiltration volume of 9 l in their first week on CPAP.
Two haemodialysis patients required fluid removal of
over 18 l in the first 7 days due to clinical features of pul-
monary oedema and fluid overload.
In the non-dialysis group only 14% (n = 2) were sys-
temically anticoagulated, in contrast to 56% (n = 5) in
the dialysis group (not including the low molecular
weight heparin they received on dialysis). Kaplan-Meier
survival curves show that the administration of anticoa-
gulation results in a statistically significant difference in
survival rate between the two groups (Fig. 2).
Discussion
Our study demonstrated an improved survival in dialysis
patients treated with ward-based CPAP compared to
non-dialysis patients. The reasons behind the improved
outcomes in our dialysis cohort are likely to be
Table 2 Results of univariate Cox regression modelling,
showing hazard ratios (HR), 95% confidence intervals (CI) and p-
values
Variable HR (95% CI) p-value
Dialysis (No)
Yes a0.071 (0.009,0.560) 0.012
Age (Years) (0–60)
61–70 0.288 (0.336,24.65) 0.335
71–80 2.258 (0.234,21.75) 0.481
81 + 7.600 (0.768,75.15) 0.083
Age (Years) 1.050 (0.987,1.117) 0.119
Sex (Female)
Male 0.511 (0.161,1.626) 0.256
CPAP Days 0.896 (0.775,1.035) 0.135
Max PEEP 0.964 (0.838,1.284) 0.734
Anticoagulated (No)
Yes a0.122 (0.016,0.952) 0.045
aSignificant at 5% significance level
- Variable column bracket key: (Units) (Baseline reference category)
Fig. 1 Kaplan-Meier survival curves showing the probability of
survival up to 30 days for COVID-19 positive CPAP patients, stratified
by dialysis group
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multifactorial and potentially confounded. Our study
was limited by a small sample size and by our compara-
tive group not being equally matched across all demo-
graphics and co-morbidities. The unmatched cohorts
means there is possible confounding of the relationship
between dialysis and the survival outcome and this
would be an area for further investigation.
It is widely recognised that dialysis patients have al-
tered immunity secondary to the chronic uraemic state,
which may be compounded by immunosuppressant use
[9]. Initial reports suggested dialysis patients would be at
higher risk due to increased prevalence of hypertension,
diabetes mellitus and cardiovascular disease, but also the
need to attend dialysis units regularly; often via public
transport making social distancing and isolating difficult
[10–12]. One of the proposed mechanisms for Acute Re-
spiratory Distress Syndrome (ARDS) and Multiorgan
Failure (MOF) in the context of COVID-19 is the cyto-
kine release storm (CRS) [13]. As a direct result of viral
invasion into the host alveolar cell via the ACE2 receptor
[14], there is a cascade of reactions resulting in wide-
spread release of proinflammatory cytokines which in-
clude interleukins, particularly interleukin-6(IL-6), and
tumour-necrosis factor alpha (TNF-α) [15]. It has been
hypothesised that the immunomodulatory effect of the
uraemic environment in dialysis patients tempers this
cytokine response to some extent [16]. In addition to
lower levels of inflammatory cytokines seen in haemodi-
alysis patients compared to non-dialysis controls,
haemodialysis patients have also been shown to have
lower numbers of T cells, T helper cells, T killer cells,
NK cells and B lymphocytes; with cell numbers reduced
further still in haemodialysis patients with COVID-19
disease compared to those without [17]. When
comparing mortality, higher levels of inflammatory
markers including IL-6 were found in haemodialysis pa-
tients who died compared with survivors [18]. So, whilst
on the one hand, dialysis patients are prone to increased
infections in general because of their immunosuppressed
state, on the other it appears to confer some protection
from the harmful cytokine mediated effects of COVID-
19. Indeed, it has been shown that dialysis patients have
milder clinical features of COVID-19 when compared to
the general population [17, 19, 20]. Whilst our study
looks at those patients that had a more severe course of
illness it is important to note that only those who were
symptomatic were screened for COVID-19 and therefore
many asymptomatic patients may have been missed,
making it hard to determine the true incidence of
COVID-19 in our dialysis group.
We report a 30 day mortality rate of 11.1%, with an
overall mortality rate of 22.2% at the time of writing,
within our dialysis patients that received CPAP. Various
reports have shown differing mortality rates amongst the
dialysis patients they investigated; ranging from no
deaths [12, 21] and very mild disease [20] in the initial
reports published from China, up to as high as 44% in
Italy [22]. Excluding those with no mortality, Fig. 3 de-
picts the worldwide mortality rates across the dialysis
groups, which on average are in keeping with our find-
ings. However it is important to note the small sample
size in all studies, which in addition to discrepancy in
clinical practice and dialysis populations, may account
for the highly variable mortality rates. Furthermore, our
mortality rate refers to dialysis patients who received
ward-based CPAP, a group who by definition are likely
to have been more acutely unwell due to the need for re-
spiratory support.
Within our study the mortality rate of non-dialysis pa-
tients was very high at just under 80%, which is substan-
tially higher than the region of 5% seen in the general
population worldwide [28], although this includes all
COVID-19 infections and not the most severe cases
needing CPAP as reflected by our cohort. In addition,
our cohort of non-dialysis patients required inpatient
care and were deemed unsuitable for escalation to ICU.
This was due to multiple factors reflected by their co-
morbidities, average CFS of 4 and median age over 70.
This cohort is therefore not representative of the general
population, and not reflective of our centre’s overall
mortality rate for COVID-19.
Regarding escalation and treatment of COVID-19
positive dialysis patients to ICU, very little is known. As-
sessment for admission to intensive care is challenging
and more recently the use of CFS is being used to deter-
mine patients’ risk of hospital associated mortality, high
CFS are associated with worse outcomes [29]. With
regards to respiratory support, of the two published
Fig. 2 Kaplan-Meier survival curves showing the probability of
survival up to 30 days for COVID-19 positive CPAP patients, stratified
by anticoagulation
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studies, both hailing from New York USA, the mortality
rate in mechanically ventilated dialysis patients was very
high at 75% [23] and 94.7% [18]. More outcome data in
this area is required to drawn any firm conclusion, how-
ever if the significant mortality rate is replicated else-
where then providing ward-based CPAP or level 2
respiratory support in a feasible way holds all the more
weight.
In our cohort of dialysis patients almost all of those re-
ceiving CPAP had either daily or alternate day ultrafiltra-
tion via haemodialysis. Accumulating evidence has
shown that positive fluid balance is a strong and inde-
pendent predictor of poor outcomes in the critically ill.
Positive fluid balance is often the result of fluid adminis-
tration in acutely unwell patients in addition to mainten-
ance fluids that are prescribed during admissions [30,
31]. The administration of fluids in non dialysis groups
is often more common and can results in fluid overload
and pulmonary oedema, which can lead to worse out-
comes [32]. The role of significant fluid removal in our
patients reflects other common practices prior to
COVID-19 in a critical care setting [33]. A prospective
study in 2002 showed that daily dialysis resulted in lower
rates of multi organ failure and fluid imbalance com-
pared to alternate day dialysis [34]. Specifically, in the
setting of ARDS, influx of inflammatory cells and cyto-
kines results in marked interstitial oedema and stiff
lungs, for which higher volumes of ultrafiltration may
have a beneficial effect. Studies reporting specific param-
eters for renal replacement therapy and fluid removal in
dialysis patients with COVID-19 are scarce, however of
those case reports where the patient survived there were
large volumes of ultrafiltration, namely 8.5 l over 53 h of
Continuous Veno-Venous Haemofiltration (CVVH) [21]
and 7 kg reduction in body weight over five days [24].
Conversely, an early study reported no difference in dis-
ease severity related to dialysis frequency, although no
ultrafiltration volumes were provided [11]. It is import-
ant to note that in our cohort we used intermittent
haemodialysis in comparison to other studies where pa-
tients in the critical care setting are likely to receive con-
tinuous renal replacement therapy in the form of
CVVH. The full extent of increased metabolic by prod-
uct and possible inflammatory cytokine clearance is un-
known between these modalities. As such, making a
direct comparison between HD and CVVH in relation to
outcomes amongst COVID-19 patients and critically ill
dialysis patients is limited.
Within our cohort the use of anticoagulation appeared
to be associated with reduced mortality, with improved
survival in those patients who were systemically anticoa-
gulated. This result was statistically significant. This is in
keeping with other studies, where treatment with hep-
arin was associated with improved survival in severe
COVID-19 disease [35, 36]. Fifty-six percent of our dia-
lysis patients compared to 14% of non-dialysis patients
Fig. 3 Mortality rates amongst COVID-19 dialysis patients from case reports in different centres worldwide, expressed as percentages [11, 14,
17–19, 22–27]
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were systemically anticoagulated although the survival
benefit may be confounded by the impact of dialysis on
this group. The lower rates of systemic anticoagulation
seen in the non-dialysis group likely reflect the fact that
data collection occurred early in our experience of
COVID-19. Our anticoagulation practice now is in keep-
ing with published guidance. COVID-19 is now well
recognised as a procoagulant state, with particular em-
phasis on higher levels of d-dimer and fibrin degradation
products being associated with poorer outcomes [35,
36]. This was further evidenced by three of our dialysis
patients who developed A-V fistula thrombosis during
their COVID-19 illness, requiring alternative vascular ac-
cess. Data related specifically to anticoagulation in dialy-
sis cohorts is scarce. Within a French study of patients
admitted to ICU, despite either prophylactic or thera-
peutic anticoagulation, 96.6% of patients receiving con-
tinuous RRT developed a clotted dialysis circuit [37]. In
addition they reported increased thrombotic complica-
tions, although the impact of ultrafiltration in these
groups may have been contributory [37]. Within our
centre dialysis patients are routinely anticoagulated on
dialysis with the low molecular weight heparin (LMWH)
tinzaparin, unless there is a specific contra-indication to
doing so, which may further contribute to the systemic
anticoagulation they were otherwise receiving whilst ad-
mitted as an inpatient. Outside of the primary effect of
preventing thrombus formation, treatment with heparin
has been suggested to be beneficial inpatients with
COVID-19 due to a variety of different mechanisms,
including anti-inflammatory properties, mitigating and
protecting against damage to the vascular endothelium,
and interfering with the coagulation systems role in
the pathogenesis of ARDS [38]. Furthermore, heparin
has been shown to have a potential anti-viral effect in
COVID-19, which may contribute to the more
favourable outcomes seen in anticoagulated patients
[38–40]. Given the above findings, more studies are
required looking at the specific role of anticoagulation
in dialysis patients and those receiving acute RRT
during the COVID-19 pandemic.
Conclusion
Whilst there are limitations to the study based on the
small sample size, it is to the best of our knowledge, the
largest series of dialysis dependent COVID-19 patients
treated with CPAP in non ICU settings. We show a 30
day mortality rate of 11.1% which is significantly lower
than that of the non-dialysis patients (78.6%). The role
of ultrafiltration and anticoagulation may also be a vari-
able that has contributed to reduced mortality rate in
this cohort. There was no statistically significant differ-
ence between age and gender, but there was some
evidence that increasing age led to increased rate of
mortality.
By definition, dialysis dependent patients have evi-
dence of organ failure. They are typically older with
higher clinical frailty scores and co-morbidities such as
hypertension, ischemic heart disease and diabetes melli-
tus making them vulnerable to COVID-19 as demon-
strated by our cohort. These patients are often not
considered suitable for intensive care management and
as a result are treated at a ward-based level. Despite the
limitations as described above, we believe this study pro-
vides impetus for further work clarifying the role of
CPAP in treating COVID-19 dialysis dependent patients.
Furthermore, this study shows that with education and a
multi-disciplinary approach, CPAP can be successfully
delivered outside the usual setting to not only relieve
pressures on ICU capacity but allow simultaneous dialy-
sis on non-respiratory wards.
Abbreviations
CPAP: Continuous Positive Airway Pressure; ICU: Intensive Care Units;
RRT: Renal Replacement Therapy; HHD: Home Haemodialysis; ICHD: In-centre
Haemodialysis; PD: Peritoneal Dialysis; CSF: Clinical Frailty Scores;
IQR: Interquartile Range; PEEP: Positive End Expiratory Pressure; ARDS: Acute
Respiratory Distress Syndrome; MOF: Multi-organ Failure; CVVH: Continuous
Veno-Venous Haemofiltration; HDF: Hemodiafiltration; LMWH: Low Molecular
Weight Heparin
Supplementary Information




The authors would like to acknowledge the Renal Department at Royal
Preston Hospital in addition to the Respiratory Department for their clinical
support during the study period and sharing of data.
Authors’ contributions
LF lead author, AF analysed and interpreted the data using statistical models
as described in the paper. AD supervised the project and MS, JS and PV
were all involved in the writing and review of the manuscript. All authors
contributed to the writing of the manuscript and all authors have read and
approved the final manuscript.
Funding
No funding was required.
Availability of data and materials
The data analysed for this study is available from the corresponding author
on request.
Declarations
Ethics approval and consent to participate
Approval for this study was obtained by The Centre for Health Research and
Innovation on behalf of Lancashire Teaching Hospitals NHS Foundation Trust
(Ref: SE-296). The study was approved as a service evaluation, therefore for-
mal research ethics committee review was not required.
Consent for publication
Not applicable.
Floyd et al. BMC Nephrology          (2021) 22:144 Page 7 of 9
Competing interests
All authors declare that they have no competing interests.
Author details
1Department of Nephrology, Royal Preston Hospital, Lancashire Teaching
Hospitals NHS Foundation Trust, Preston, UK. 2University of Central
Lancashire, Lancashire, UK.
Received: 2 September 2020 Accepted: 8 April 2021
References
1. UK Renal Registry. COVID-19 surveillance report for renal centres in the UK -
up to 6th May 2020. Ren Assoc. 2020; (May). Available from: https://renal.
org/wp-content/uploads/2020/05/ALL_REGIONS_CENTRES_covid_report.pdf
2. NHS. Specialty guides for patient management during the coronavirus
pandemic Guidance for the role and use of non-invasive respiratory support
in adult patients with coronavirus (confirmed or suspected). 2020;19.
Available from: https://www.nice.org.uk/guidance/ng159
3. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, Llontop C, Guerder A,
Trosini-Desert V, et al. Continuous positive airway pressure to avoid
intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-
control study. Eur Respir J. 2020;1:2001692 Available from: http://erj.
ersjournals.com/content/early/2020/05/13/13993003.01692-2020.abstract.
4. Care Quality Commission. Inspection framework: NHS acute hospitals Core
service: critical care, vol. 08; 2016. (July 2016). Available from: http://www.
cqc.org.uk/sites/default/files/20160729_NHS_core_service_inspection_fra
mework_urgent_and_emergency_services.pdf
5. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I,
et al. A global clinical measure of fitness and frailty in elderly people. C Can
Med Assoc J. 2005;173(5):489–95.
6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is
associated with in-hospital death of patients with COVID-19. Kidney Int.
2020;97(5):829–38. https://doi.org/10.1016/j.kint.2020.03.005.
7. Coggon D, Croft P, Cullinan P, Williams A. Assessment of workers personal
vulnerability to covid-19 using covid-age. medRxiv. 2020;70(7):461.
8. Coggon D, Croft P, Cullinan P, Williams T. Covid-19 Medical Risk Assessment.
2021. https://alama.org.uk/covid-19-medical-risk-assessment/.
9. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al.
Aspects of Immune Dysfunction in End-stage Renal Disease. Clin J Am Soc
Nephrol. 2008;3(5):1526–33.
10. Kliger AS, Cozzolino M, Jha V, Harbert G, Ikizler TA. Managing the COVID-19
pandemic: international comparisons in dialysis patients. Kidney Int. 2020;
98(1):12–6. https://doi.org/10.1016/j.kint.2020.04.007.
11. Xiong F, Tang H, Liu L, Tu C, Tian J-B, Lei C-T, et al. Clinical Characteristics of
and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan,
China. J Am Soc Nephrol. 2020;31(7):1387–97 Available from: http://jasn.a
snjournals.org/content/31/7/1387.abstract.
12. Tang B, Li S, Xiong Y, Tian M, Yu J, Xu L, et al. Coronavirus disease 2019
(COVID-19) pneumonia in a hemodialysis patient. Kidney Med. 2020;2(3):
354–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32292904. https://
doi.org/10.1016/j.xkme.2020.03.001.
13. Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ,
et al. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Cardiorenal Med. 2020;10(5):277 Available from: https://www.karger.com/
DOI/10.1159/000509483.
14. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al.
Management of Patients on Dialysis and with kidney transplantation during
the SARS-CoV-2 (COVID-19) pandemic in Brescia. Italy Kidney Int Reports.
2020;5(5):580–5. https://doi.org/10.1016/j.ekir.2020.04.001.
15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan. China Lancet.
2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
16. Rabb H. Kidney diseases in the time of COVID-19: major challenges to
patient care. J Clin Invest. 2020;130(6):2749–51. https://doi.org/10.1172/
JCI138871.
17. Ma Y, Diao B, Lv X, Zhu J, Liang W, Liu L, et al. COVID-19 in hemodialysis
(HD) patients: Report from one HD center in Wuhan, China. medRxiv. 2020;
Available from: http://medrxiv.org/content/early/2020/06/17/2020.02.24.2002
7201.abstract.
18. Fisher M, Yunes M, Mokrzycki MH, Golestaneh L, Alahiri E, Coco M. Chronic
Hemodialysis Patients Hospitalized with COVID-19 - Short-term Outcomes in
Bronx, New York. Kidney. 2020. https://doi.org/10.34067/KID.0003672020
Available from: http://kidney360.asnjournals.org/content/early/2020/06/18/
KID.0003672020.abstract.
19. Goicoechea M, Sánchez Cámara LA, Macías N. Muñoz de Morales a, Rojas
ÁG, Bascuñana a, et al. COVID-19: clinical course and outcomes of 36
hemodialysis patients in Spain. Kidney Int. 2020;98(1):27–34. https://doi.org/1
0.1016/j.kint.2020.04.031.
20. Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in hemodialysis
patients: a report of 5 cases. Am J Kidney Dis. 2020;76(1):141–3. https://doi.
org/10.1053/j.ajkd.2020.03.009.
21. Fu D, Yang B, Xu J, Mao Z, Zhou C, Xue C. COVID-19 infection in a patient
with end-stage kidney disease. Nephron. 2020;144(5):245–7 Available from:
https://www.karger.com/DOI/10.1159/000507261.
22. Scarpioni R, Manini A, Valsania T, De Amicis S, Albertazzi V, Melfa L, et al.
Covid-19 and its impact on nephropathic patients: the experience at
Ospedale “Guglielmo da Saliceto” in Piacenza. G Ital di Nefrol organo Uff
della Soc Ital di Nefrol. 2020;37:2.
23. Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J,
et al. Presentation and Outcomes of Patients with ESKD and COVID-19. J
Am Soc Nephrol. 2020;31(7):1409–15 Available from: http://jasn.asnjournals.
org/content/31/7/1409.abstract.
24. Kuroki Y, Hiyama K, Minami J, Takeuchi M, Shojima M, Matsueda S, et al. The
first case of COVID-19 pneumonia in a hemodialysis patient in Japan. CEN
Case Rep. 2020;1:1–5 Available from: https://pubmed.ncbi.nlm.nih.gov/32
557209.
25. Esposito P, Russo R, Conti N, Falqui V, Massarino F, Moriero E, et al.
Management of COVID-19 in hemodialysis patients: the Genoa experience.
Hemodial Int. 2020;24(3):423–7. https://doi.org/10.1111/hdi.12837.
26. Gallieni M, Sabiu G, Scorza D. Delivering Safe and Effective Hemodialysis in
Patients with Suspected or Confirmed COVID-19 Infection: A Single-Center
Perspective from Italy. Kidney360. 2020;1(5):403–9 Available from: http://
kidney360.asnjournals.org/content/1/5/403.abstract.
27. Jung H-Y, Lim J-H, Kang SH, Kim SG, Lee Y-H, Lee J, et al. Outcomes of
COVID-19 among Patients on In-Center Hemodialysis: an experience from
the epicenter in South Korea. J Clin Med. 2020;9(6):1688.
28. Hens N, Vranck P, Molenberghs G. The COVID-19 epidemic, its mortality, and
the role of non-pharmaceutical interventions. Eur Heart J Acute Cardiovasc
Care. 2020;9(3):204–8. https://doi.org/10.1177/2048872620924922.
29. Sablerolles RSG, Lafeber M, van Kempen JAL, van de Loo BPA, Boersma E,
Rietdijk WJR, et al. Association between Clinical Frailty Scale score and
hospital mortality in adult patients with COVID-19 (COMET): an international,
multicentre, retrospective, observational cohort study. Lancet Heal Longev.
2021;2(3):e163–70. https://doi.org/10.1016/S2666-7568(21)00006-4.
30. Sirvent J-M, Ferri C, Baró A, Murcia C, Lorencio C. Fluid balance in sepsis and
septic shock as a determining factor of mortality. Am J Emerg Med. 2015;
33(2):186–9. https://doi.org/10.1016/j.ajem.2014.11.016.
31. Acheampong A, Vincent J-L. A positive fluid balance is an independent
prognostic factor in patients with sepsis. Crit Care. 2015;19(1):251. https://
doi.org/10.1186/s13054-015-0970-1.
32. Besen BAMP, Gobatto ALN, Melro LMG, Maciel AT, Park M. Fluid and
electrolyte overload in critically ill patients: an overview. World J Crit care
Med. 2015;4(2):116–29. https://doi.org/10.5492/wjccm.v4.i2.116.
33. Gillum DM, Dixon BS, Yanover MJ, Kelleher SP, Shapiro MD, Benedetti RG,
et al. The role of intensive dialysis in acute renal failure. Clin Nephrol. 1986;
25(5):249–55 Available from: http://europepmc.org/abstract/MED/3720035.
34. Schiffl H, Lang SM, Fischer R. Daily Hemodialysis and the Outcome of Acute
Renal Failure. N Engl J Med. 2002;346(5):305–10. https://doi.org/10.1056/
NEJMoa010877.
35. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is
associated with decreased mortality in severe coronavirus disease 2019
patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. https://
doi.org/10.1111/jth.14817.
36. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated
with poor prognosis in patients with novel coronavirus pneumonia. J Thromb
Haemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.
37. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X,
et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a
multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089
Available from: https://pubmed.ncbi.nlm.nih.gov/32367170.
Floyd et al. BMC Nephrology          (2021) 22:144 Page 8 of 9
38. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020 May;
18(5):1020–2. https://doi.org/10.1111/jth.14821.
39. Pisani A, Rizzo M, Angelucci V, Riccio E. COVID-19 experience in
hemodialysis patients: a Cue for therapeutic heparin-based strategies?
Nephron. 2020;144(8):383–5 Available from: https://www.karger.com/DOI/1
0.1159/000508638.
40. Mycroft-West C, Su D, Elli S, Guimond S, Miller G, Turnbull J, et al. The 2019
coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding
Domain undergoes conformational change upon heparin binding. bioRxiv.
2020;1:1 Available from: http://biorxiv.org/content/early/2020/03/02/2020.
02.29.971093.abstract.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Floyd et al. BMC Nephrology          (2021) 22:144 Page 9 of 9
